Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

Arsanis, Inc.. (3/1/17). "Press Release: Arsanis to Present at the Cowen and Company 37th Annual Health Care Conference". Waltham, MA & Vienna.

Region Region Boston, MA
  Country United States (USA)
Organisations Organisation Arsanis Inc. (Nasdaq: ASNS)
  Group Arsanis (Group)
  Organisation 2 Cowen & Company LLC
Products Product Cowen & Co. Annual Health Care Conference 2017 Boston
  Product 2 ASN100 (Arsanis)
Index term Index term Arsanis–Cowen: investor conference, 201703 supply service Arsanis presents at Cowen & Co Annual Health Care Conference 2017
Persons Person Russo, René (Arsanis 201702 CEO)
  Person 2 Gray, Michael (Mike) (Arsanis 201702 CFO + CBO)

Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies (mAbs) for pre-emptive and post-infection treatment of serious infectious diseases, announced today that René Russo, PharmD, BCPS, chief executive officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference in Boston, MA.

The presentation will take place on Wednesday, March 8, 2017, at 10:00 a.m. EDT.

About Arsanis, Inc.

Arsanis is a clinical-stage biotechnology company leading the development of targeted monoclonal antibodies (mAbs) for pre-emptive therapy and treatment of serious infectious diseases. The company’s current programs address pathogenic processes selectively, aiming to preserve the healthy microbiome and potentially allowing Arsanis to address critical infections without contributing to the problem of resistance. The company is building a broad product pipeline addressing the most important infectious diseases that threaten patients globally. Its lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical study for the prevention of S. aureus pneumonia in high-risk patients.

Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH). For more information, please visit the Arsanis website at


Media Contact:
Ten Bridge Communications
Krystle Gibbs, 508-479-6358


Investor Contact:
Michael Gray, 781-819-5201
Chief Financial and Chief Business Officer

Record changed: 2023-06-05


Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Arsanis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top